肾性低尿酸血症并反复急性肾损伤1例并文献复习

doi:10.3969/j.issn.1004-583X.2025.02.013

临床荟萃 ›› 2025, Vol. 40 ›› Issue (2): 168-171.doi: 10.3969/j.issn.1004-583X.2025.02.013

肾性低尿酸血症并反复急性肾损伤1例并文献复习

张慧, 张文博, 梁文琪, 霍延红()

解放军总医院第一医学中心肾脏病医学部解放军总医院第七医学中心肾脏病科,北京 100700

收稿日期:2024-11-23 出版日期:2025-02-20 发布日期:2025-03-05
通讯作者: 霍延红 E-mail:13691110882@139.com

Idiopathic renal hypouricemia combined with repeated acute kidney injury: A case report and literature review

Zhang Hui, Zhang Wenbo, Liang Wenqi, Huo Yanhong()

Department of Nephrology, the First Medical Center, Chinese PLA General Hospital, Department of Nephrology, the Seventh Medical Center, Chinese PLA General Hospital, Beijing 100700, China

Received:2024-11-23 Online:2025-02-20 Published:2025-03-05
Contact: Huo Yanhong E-mail:13691110882@139.com

摘要/Abstract

摘要：

目的探讨特发性肾性低尿酸血症(idiopathic renal hypouficemia, iRHUC)的临床特征及诊疗思路。方法回顾性分析1例两次发生运动诱发的急性肾损伤(exercise-induced acute kidney injury,EIAKI)、最终通过基因检测确诊为iRHUC患者的病历资料,分析其临床特征、诊疗思路及预后,并结合相关文献进行复习。结果 1名23岁男性患者,两次在剧烈运动后发生急性肾损伤(acute kidney injury,AKI),肾功能恢复正常但持续存在低尿酸血症,尿酸排泄分数(fractional excretion of uric acid,FEUA)明显升高,全外显基因检测示SLC22A12基因纯合突变,最终确诊为iRHUC。结论 iRHUC临床诊断病例不多,临床医生需加强对该病的认识,避免漏诊、误诊,以指导治疗和预防并发症。

关键词: 急性肾损伤, 肾性低尿酸血症, SLC22A12, 基因突变

Abstract:

Objective To investigate the clinical characteristics and diagnostic and treatment of idiopathic renal hypouricemia (iRHUC). Methods Clinical data of a patient who suffered from exercise-induced acute kidney injury (EIAKI) twice and was finally diagnosed with iRHUC by genetic testing were retrospectively collected. The clinical characteristics, diagnostic process, treatment options and prognosis were analyzed, and the relevant literatures were reviewed. Results A 23-year-old man suffered from acute kidney injury (AKI) twice after intensive exercise. The renal function returned to normal but hypouricemia persisted. Fractional excretion of uric acid (FEUA) was significantly elevated. The mutational analysis revealed a homozygous mutation in the SLC22A12 gene, and he was finally diagnosed with iRHUC. Conclusion iRHUC cases are not commonly reported, and we should strengthen our understanding of the disease to avoid missed diagnosis and misdiagnosis, so as to guide treatment and prevent complications.

Key words: acute kidney injury, renal hypouricemia, SLC22A12, gene mutation

中图分类号:

R692.5

张慧, 张文博, 梁文琪, 霍延红. 肾性低尿酸血症并反复急性肾损伤1例并文献复习[J]. 临床荟萃, 2025, 40(2): 168-171.

Zhang Hui, Zhang Wenbo, Liang Wenqi, Huo Yanhong. Idiopathic renal hypouricemia combined with repeated acute kidney injury: A case report and literature review[J]. Clinical Focus, 2025, 40(2): 168-171.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.02.013

https://lchc.magtechjournal.com/CN/Y2025/V40/I2/168

图/表 1

参考文献 18

[1]	曾静, 王建华, 汤如, 等. 2009-2013年军队体检人群疾病检出率分析[J]. 解放军医学院学报, 2016, 37(2): 112-116.
[2]	Bellomo G, Selvi A. Uric acid: The lower the better?[J]. Contrib Nephrol, 2018, 192: 69-76. doi: 10.1159/000484280 pmid: 29393097
[3]	Koto R, Sato I, Kuwabara M, et al. Temporal trends in the prevalence and characteristics of hypouricaemia: A descriptive study of medical check-up and administrative claims data[J]. Clin Rheumatol, 2022, 41(7): 2113-2119.
[4]	Kawamura Y, Nakayama A, Shimizu S, et al. A proposal for practical diagnosis of renal hypouricemia: Evidenced from genetic studies of nonfunctional variants of URAT1/SLC22A12 among 30, 685 Japanese individuals[J]. Biomedicines, 2021, 9(8): 1012.
[5]	Koo BS, Jeong HJ, Son CN, et al. Distribution of serum uric acid levels and prevalence of hyper- and hypouricemia in a Korean general population of 172, 970[J]. Korean J Intern Med, 2021, 36(Suppl): S264-S272.
[6]	尹逸丛, 吴洁, 禹松林, 等. 北京协和医院低尿酸血症患病率情况调查[J]. 中华检验医学杂志, 2018, 41(3): 237-241.
[7]	Wang C, Wang J, Liu S, et al. Idiopathic renal hypouricemia: A case report and literature review[J]. Mol Med Rep, 2019, 20(6): 5118-5124. doi: 10.3892/mmr.2019.10726 pmid: 31638209
[8]	Nakayama A, Matsuo H, Abhishek A, et al. First clinical practice guideline for renal hypouricaemia: A rare disorder that aided the development of urate-lowering drugs for gout[J]. Rheumatology (Oxford), 2021, 60(9): 3961-3963.
[9]	Mount DB. Molecular physiology and the four-component model of renal urate transport[J]. Curr Opin Nephrol Hypertens, 2005, 14(5): 460-463.
[10]	Yanai H, Adachi H, Hakoshima M, et al. A possible therapeutic application of the selective inhibitor of urate transporter 1, dotinurad, for metabolic syndrome, chronic kidney disease, and cardiovascular diseaset[J]. Cells, 2024, 13(5): 450.
[11]	Major TJ, Dalbeth N, Stahl EA, et al. An update on the genetics of hyperuricaemia and gout[J]. Nat Rev Rheumatol, 2018, 14(6): 341-353. doi: 10.1038/s41584-018-0004-x pmid: 29740155
[12]	王纯, 李红霞, 丁娟娟, 等. SLC2A9突变致肾性低尿酸血症一家系报告并文献复习[J]. 临床肾脏病杂志, 2021, 21(10): 877-881.
[13]	Kim HO, Ihm CG, Jeong KH, et al. A case report of familial renal hypouricemia confirmed by genotyping of SLC22A12, and a literature review[J]. Electrolyte Blood Press, 2015, 13(2): 52-57.
[14]	Yang Y, Mu X, Wu Z, et al. Renal hypouricemia complicated with kidney stone: A case report[J]. Front Med (Lausanne), 2024, 7(11): 1218232.
[15]	Perdomo-Ramírez A, Ramos-Trujillo E, Claverie-Martín F, et al. New SLC22A12 (URAT1) variant associated with renal hypouricemia identified by whole-exome sequencing analysis and bioinformatics predictions[J]. Genes (Basel), 2023, 14(9): 1823.
[16]	Zhou Z, Ma L, Zhou J, et al. Renal hypouricemia caused by novel compound heterozygous mutations in the SLC22A12 gene: A case report with literature review[J]. BMC Med Genet, 2018, 19(1): 142. doi: 10.1186/s12881-018-0595-8 pmid: 30097038
[17]	Miake J, Hisatome I, Tomita K, et al. Impact of hyper- and hypo-uricemia on kidney function[J]. Biomedicines, 2023, 11(5): 1258.
[18]	Dinour D, Bahn A, Ganon L, et al. URAT1 mutations cause renal hypouricemia type 1 in Iraqi Jews[J]. Nephrol Dial Transplant, 2011, 26(7): 2175-2181.

肾性低尿酸血症并反复急性肾损伤1例并文献复习

Idiopathic renal hypouricemia combined with repeated acute kidney injury: A case report and literature review

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 18

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周颖, 周芳芳. 社区获得性急性肾损伤的流行病学研究进展[J]. 临床荟萃, 2024, 39(9): 847-850.
[2]	吕莎莎, 宋金兰, 石健. m.3243A>G突变相关线粒体糖尿病1例并文献复习[J]. 临床荟萃, 2024, 39(2): 160-163.
[3]	张琳丽, 麻晓红. 老年髋部骨折术后发生急性肾损伤的临床特点及危险因素分析[J]. 临床荟萃, 2021, 36(5): 442-445.
[4]	陈易欣, 周芳芳, 罗群. 急性肾损伤集束化治疗的研究进展[J]. 临床荟萃, 2021, 36(4): 370-373.
[5]	孙如梦, 李英. 抗凝相关性肾病研究进展[J]. 临床荟萃, 2020, 35(12): 1148-1152.
[6]	陈星星, 雷晓燕, 孙永红, 胡筱霞, 赵淑珍 . 基于基因检测诊断晚婴型神经元蜡样脂褐质沉积症1例[J]. 临床荟萃, 2020, 35(11): 1019-1025.
[7]	尹万红，中国重症超声研究组. 液体过负荷与急性肾损伤[J]. 临床荟萃, 2019, 34(7): 604-607.
[8]	晁彦公，中国重症超声研究组. 脓毒症急性肾损伤时血管活性药物的选择[J]. 临床荟萃, 2019, 34(7): 599-603.
[9]	刘丽霞1, 王小亭2, 晁彦公3, 张宏民2, 武钧4，尹万红5, 张丽娜6, 何伟7, 朱然8, 丁欣2, 张倩1, 胡振杰1, 中国重症超声研究组. 脓毒症急性肾损伤：一种微循环疾病[J]. 临床荟萃, 2019, 34(7): 595-598.
[10]	胡成欢，张丽娜，中国重症超声研究组. 肾脏灌注压多少合适？[J]. 临床荟萃, 2019, 34(7): 590-594.
[11]	姚玉龙1，李奕然2，武钧3，中国重症超声研究组. 肾脏可复性评估[J]. 临床荟萃, 2019, 34(7): 608-613.
[12]	朱然，中国重症超声研究组. 正确应用速尿应激试验[J]. 临床荟萃, 2019, 34(7): 614-616.
[13]	郝晓萍，邬碧波，张黎明，俞华，唐琦. 尿肝型脂肪酸结合蛋白对急性失代偿性心力衰竭患者发生急性肾损伤的预测[J]. 临床荟萃, 2019, 34(4): 326-329.
[14]	冯三丽1, 2，张静楠2，乔淑凯2，王文飞1，李扬2，邢丽娜2，郭晓楠2. 原发性骨髓纤维化伴阵发性睡眠性血红蛋白尿1例并文献复习[J]. 临床荟萃, 2019, 34(12): 1119-1122.
[15]	刘华杰1，高霞2. 新生儿早期肾损伤的评估：经典指标到代谢组学的革新[J]. 临床荟萃, 2018, 33(9): 825-828.